<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394650</url>
  </required_header>
  <id_info>
    <org_study_id>CC-98633-MM-001</org_study_id>
    <secondary_id>U1111-1251-3435</secondary_id>
    <nct_id>NCT04394650</nct_id>
  </id_info>
  <brief_title>A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juno Therapeutics, a Subsidiary of Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juno Therapeutics, a Subsidiary of Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric&#xD;
      Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma.&#xD;
&#xD;
      The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The&#xD;
      dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of&#xD;
      increasing dose levels of CC-98633 to establish a recommended Phase 2 dose (RP2D); and the&#xD;
      dose-expansion part (Part B) of the study is to further evaluate the safety,&#xD;
      pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">November 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From the time of informed consent and follow up to 2 years after infusion of CC-98633:</time_frame>
    <description>incidence and severity of AEs. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>The proportion of subjects with a partial response (PR) or better by the IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to 2 years after CC-99633 infusion</time_frame>
    <description>The proportion of subjects achieving stringent CR or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>The time from first response (sCR, CR, VGPR, or PR) to progressive disease (PD) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Time from CC-98633 infusion to the first documentation of response (sCR, CR, VGPR or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete response (TTCR)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Time from CC-98633 infusion to the first documentation of sCR or CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Time from CC-98633 infusion to the first documentation of PD, or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Time from CC-98633 infusion to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - maximum serum concentration (Cmax)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Maximum blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics -time to peak serum concentration (tmax)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Time to peak (maximum) blood concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under curve (AUC)</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very good partial response (VGPR) or better</measure>
    <time_frame>Up to 2 years after CC-98633 infusion</time_frame>
    <description>Is define as proportion of subjects achieving sCR, CR, or VGPR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CC-98633</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CC-98633</intervention_name>
    <description>Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 98633.&#xD;
During CC 98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 98633 product, subjects will receive treatment with CC 98633 therapy.&#xD;
Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection.</description>
    <arm_group_label>CC-98633</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years.&#xD;
&#xD;
          2. Signed written informed consent prior to any study procedure.&#xD;
&#xD;
          3. Relapsed and/or refractory multiple myeloma (MM). Subjects must have received at least&#xD;
             3 prior antimyeloma treatment regimens. Subjects must have documented progressive&#xD;
             disease during or within 12 months of completing treatment with the last anti-myeloma&#xD;
             treatment regimen before study entry. Also, subjects with documented evidence of&#xD;
             progressive disease within the previous 6 months and who are refractory or&#xD;
             nonresponsive to their most recent anti-myeloma treatment regimen afterwards will be&#xD;
             also eligible.&#xD;
&#xD;
             Subjects must have previously received all of the following therapies:&#xD;
&#xD;
               1. Autologous stem cell transplant&#xD;
&#xD;
               2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide,&#xD;
                  pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib),&#xD;
                  either alone or combination&#xD;
&#xD;
               3. Anti-CD38 (eg, daratumumab), either alone or combination&#xD;
&#xD;
          4. Measurable disease&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known active or history of central nervous system (CNS) involvement of MM&#xD;
&#xD;
          2. Active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS&#xD;
             (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes)&#xD;
             syndrome, or clinically significant amyloidosis&#xD;
&#xD;
          3. Prior treatment with CAR T-cell or another genetically modified T-cell therapy&#xD;
&#xD;
          4. Prior treatment with investigational therapy directed at BCMA&#xD;
&#xD;
          5. Uncontrolled or active infection&#xD;
&#xD;
          6. Active autoimmune disease requiring immunosuppressive therapy&#xD;
&#xD;
          7. History or presence of clinically significant CNS pathology such as seizure disorder,&#xD;
             aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar&#xD;
             disease, organic brain syndrome, or psychosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Koegel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Early Clinical Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205-2003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Myeloma Multiple</keyword>
  <keyword>CC-98633</keyword>
  <keyword>BCMA</keyword>
  <keyword>CAR-T</keyword>
  <keyword>CART</keyword>
  <keyword>BCMA CART</keyword>
  <keyword>BCMA CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

